Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$66.59 USD

66.59
461,560

+0.03 (0.05%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Varian (VAR) Q2 Earnings Lag Estimates, Gross Orders Surge

by Zacks Equity Research

Varian (VAR) gains from solid segmental contributions in Q2, raises revenue guidance.

Align Technology (ALGN) Beats on Q1 Earnings, Margins Down

by Zacks Equity Research

Align Technology (ALGN) reports promising top-line numbers on double-digit increase in Invisalign case shipments from a year ago.

Conmed (CNMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 5.56% and 2.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Reports Next Week: What You Should Expect

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes Conmed (CNMD) a New Buy Stock

by Zacks Equity Research

Conmed (CNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

XRAY vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

by Zacks Equity Research

The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.

Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Nevro's (NVRO) solid domestic and international performance aids Q4 results.

Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down

by Zacks Equity Research

Avanos (AVNS) registers solid growth in the Chronic Care and Pain Management segments in Q4.

AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) Q4 results get a boost from Nurse and Allied Solutions and Other Workforce Solutions segments.

Cooper Companies' (COO) Q1 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Strong performance by Cooper Companies' (COO) CSI and CVI segments drove the top line in first-quarter fiscal 2019.

GNC Holdings' (GNC) Q4 Earnings Miss Estimates, Margins Fall

by Zacks Equity Research

GNC Holdings' (GNC) international segment registers revenue growth in the fourth quarter.

HMS Holdings' (HMSY) Q4 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Strong performance in Analytical Services drove HMS Holdings' (HMSY) performance in Q4.

PRA Health's (PRAH) Q4 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

PRA Health (PRAH) gains from solid segmental contributions in Q4.

Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up

by Zacks Equity Research

Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.

OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues

by Zacks Equity Research

OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.

Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Penumbra (PEN) sees strength across all segments in Q4.

Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.

Patterson Companies (PDCO) Earnings Match Estimates in Q3

by Zacks Equity Research

Patterson Companies (PDCO) gains from solid segmental contributions in Q3.

Amedisys (AMED) Tops Earnings and Revenue Estimates in Q4

by Zacks Equity Research

At the Home Health and Hospice divisions, Amedisys (AMED) gains from growth in Medicare and non-Medicare revenues in Q4.

    Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

    by Zacks Equity Research

    Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.

    Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates

    by Zacks Equity Research

    The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.

    Insulet (PODD) Beats Earnings and Revenue Estimates in Q4

    by Zacks Equity Research

    The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.

    Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4

    by Zacks Equity Research

    Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.